$20.92
Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, has gone public with an IPO. Shares were priced at $18, below the expected range. and rose slightly to around $19 in their first morning of trading on May 6.
Our top picks for where to buy Bausch + Lomb Corporation stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Bausch + Lomb Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BLCO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Bausch + Lomb Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Bausch + Lomb Corporation stock price (NYSE: BLCO)
Use our graph to track the performance of BLCO stocks over time.Bausch + Lomb Corporation shares at a glance
Latest market close | $20.68 |
---|---|
52-week range | $15.90 - $20.20 |
50-day moving average | $17.27 |
200-day moving average | $17.27 |
Wall St. target price | $35.00 |
PE ratio | 33.82 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.50 |
Is it a good time to buy Bausch + Lomb Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bausch + Lomb Corporation price performance over time
Historical closes compared with the close of $20.63 from 2024-10-18
1 week (2024-10-15) | -0.53% |
---|---|
1 month (2024-09-20) | 3.36% |
3 months (2024-07-22) | 19.25% |
6 months (2024-04-22) | 40.92% |
1 year (2023-10-20) | 22.00% |
---|---|
2 years (2022-10-21) | 38.36% |
3 years (2021-10-18) | N/A |
5 years (2019-10-18) | N/A |
Is Bausch + Lomb Corporation stock undervalued or overvalued?
Valuing Bausch + Lomb Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bausch + Lomb Corporation's P/E ratio
Bausch + Lomb Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Bausch + Lomb Corporation shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Bausch + Lomb Corporation's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.
- The Cooper Companies IncCommon Stock (COO.US): 60.31
- Johnson-and-Johnson (JNJ.US): 27.34
- Aerie Pharmaceuticals (AERI.US): 0.00
Bausch + Lomb Corporation's EBITDA
Bausch + Lomb Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $720 million.
The EBITDA is a measure of a Bausch + Lomb Corporation's overall financial performance and is widely used to measure a its profitability.
To put Bausch + Lomb Corporation's EBITDA into context you can compare it against that of similar companies.
- The Cooper Companies IncCommon Stock (COO.US): USD$1 billion
- Johnson-and-Johnson (JNJ.US): USD$30.1 billion
- Aerie Pharmaceuticals (AERI.US): USD$-6545000
Bausch + Lomb Corporation financials
Revenue TTM | $3.8 billion |
---|---|
Operating margin TTM | 8.38% |
Gross profit TTM | $2.3 billion |
Return on assets TTM | 0% |
Return on equity TTM | 2.16% |
Profit margin | 4.64% |
Book value | $20.40 |
Market Capitalization | $5.9 billion |
TTM: trailing 12 months
Bausch + Lomb Corporation share dividends
We're not expecting Bausch + Lomb Corporation to pay a dividend over the next 12 months.
You may also wish to consider:
- Johnson-and-Johnson (JNJ.US) (3% forward annual dividend yield)
Bausch + Lomb Corporation overview
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada. .
Frequently asked questions
nullWhat percentage of Bausch + Lomb Corporation is owned by insiders?
Currently 0.256% of Bausch + Lomb Corporation shares are held by insiders. How many people work for Bausch + Lomb Corporation?
Latest data suggests 19,600 work at Bausch + Lomb Corporation. When does the fiscal year end for Bausch + Lomb Corporation?
Bausch + Lomb Corporation's fiscal year ends in December. Where is Bausch + Lomb Corporation based?
Bausch + Lomb Corporation's address is: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question